Oragenics

Oragenics

Oragenics

We are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets.
Type
B2b
Founded
1996
Raised
$7.7M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$3,000,000
Post-IPO equity - 2017
$4,670,000
Venture capital - 2016
Team Size
1–10
Employees
$3,000,000 Post-IPO equity
businesswire

Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement